Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Deadly bacteria in preemies: scientists hunt for clues in DNA

NCT ID NCT06973174

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a rare but often deadly infection caused by Bacillus cereus bacteria in premature newborns. Researchers will analyze the DNA of 40 bacterial samples from infected babies in French hospitals to see which genetic features make some strains more dangerous. The goal is to understand why some babies die and others survive, which could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors identify which bacterial strains are most dangerous and improve treatment for infected premature babies.
What could go wrong
This is a small, observational study with only 40 babies, so findings may not apply to all hospitals or countries. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2010

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The premature newborn included in the study were recruited from 14 NICU in 14 Tertiary Care center in France. This study is a national retrospective study

Ages

Up to 143 days

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Premature newborn (i.e born before 37 last menstrual periods) with invasive infection caused by B. cereus (strains isolated from blood culture and cerebrsopinal fluid) Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections infectious disease infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infections Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HM Marseille

    RECRUITING

    Marseille, France

  • AP-HP Hôpital Robert Debré

    RECRUITING

    Paris, France

  • CHRU de Strasbourg

    RECRUITING

    Strasbourg, France

  • CHU NICE

    RECRUITING

    Nice, Alpes Maritimes, 06000, France

  • CHU Nantes

    RECRUITING

    Nantes, France

  • CHU Nîmes

    RECRUITING

    Nîmes, France

  • CHU Rennes

    RECRUITING

    Rennes, France

  • CHU Toulouse

    RECRUITING

    Toulouse, France

  • CHU de Poitiers

    RECRUITING

    Poitiers, France

  • CHU de Tours

    RECRUITING

    Tours, France

  • CHU lille

    RECRUITING

    Lille, France

  • Hôpital Antoine Béclère, AP-HP

    RECRUITING

    Paris, France

  • Hôpital Cochin

    RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.